KYORIN Holdings, Inc. has merged its wholly owned subsidiary KYORIN Pharmaceutical. Co., Ltd and has changed its trade name to “KYORIN Pharmaceutical. Co., Ltd.” on April 2023.
This section provides information on the medium-term business plan, financial and performance results, IR library and stock.
Following our corperate philosophy, Kyorin Group is working to contribute to society’s continuous development and our sustainable growth by fulfilling our social responsibility through we business activities with new drug as our core business.
A large number of unmet medical needs are still present in the world. This section provides information on our initiatives for drug discovery, and development pipeline.
These websites are only available in Japanese.
KYORIN Pharmaceutical Co., Ltd.
